Recursion Pharmaceuticals, INC Form 4 insider transactions

Recursion Pharmaceuticals CFO Ben R. Taylor reported the acquisition of over 470,000 Class A Common Stock Restricted Stock Units and a tax-related disposal of 11,400 shares.

Recursion Pharmaceuticals' Chief Scientific Officer, David Hallett, reported the acquisition of over 526,000 shares through RSU vesting and the disposition of 11,400 shares for tax purposes.

Recursion Pharmaceuticals Director Christopher Gibson reported a series of transactions, including the sale of 40,000 Class A Common Stock under a pre-arranged trading plan.

Blake Borgeson, a Director at Recursion Pharmaceuticals, Inc., reported the sale of 220,000 shares of Class A Common Stock under a pre-arranged trading plan.

Christopher Gibson, a director at Recursion Pharmaceuticals, sold 40,000 shares of Class A Common Stock for $4.47 per share as part of a pre-arranged 10b5-1 trading plan.

Recursion Pharmaceuticals Director Blake Borgeson sold 220,000 shares of Class A Common Stock for $4.36 per share, as part of a pre-arranged 10b5-1 trading plan.

Recursion Pharmaceuticals Director Christopher Gibson reported the sale and gift of Class A Common Stock, alongside a conversion from Class B shares, all executed under a pre-arranged 10b5-1 trading plan.

Recursion Pharmaceuticals director Zavain Dar acquired 3,571 shares of Class A Common Stock as part of the company's director compensation policy.

Recursion Pharmaceuticals Director Dean Y. Li acquired 2,381 shares of Class A Common Stock as part of the company's outside director compensation policy.

Recursion Pharmaceuticals' CFO, Ben R. Taylor, sold 21,383 shares of Class A Common Stock for $4.18 per share on December 29, 2025, as part of a pre-arranged 10b5-1 trading plan.

Najat Khan, Chief R&D Commercial Officer at Recursion Pharmaceuticals, sold 124,403 shares of Class A Common Stock for approximately $548,600 under a pre-arranged trading plan.

Recursion Pharmaceuticals CEO Christopher Gibson executed a planned sale of 40,000 Class A Common Stock shares at $4.50 each, following a conversion from Class B shares.

Recursion Pharmaceuticals' CFO, Ben R. Taylor, disposed of 7,057 shares of Class A Common Stock to cover tax obligations related to restricted stock unit settlement.

Recursion Pharmaceuticals CEO Christopher Gibson executed a pre-planned sale and gift of Class A Common Stock on December 4, 2025, following a conversion of Class B shares.

Recursion Pharmaceuticals Director Blake Borgeson sold 220,000 shares of Class A Common Stock for $4.37 per share under a pre-arranged 10b5-1 trading plan.

Recursion Pharmaceuticals CFO Ben Taylor disposed of 2,271 Class A Common Stock shares to cover tax withholding obligations related to restricted stock units.

Recursion Pharmaceuticals' CFO, Ben R. Taylor, disposed of 11,908 shares of Class A Common Stock to cover tax obligations related to restricted stock unit settlement.

Recursion Pharmaceuticals' Chief R&D Commercial Officer, Najat Khan, disposed of 17,584 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit settlement.

Recursion Pharmaceuticals CEO Christopher Gibson reported transactions involving Class A Common Stock, including tax-related dispositions and a sale under a pre-arranged 10b5-1 trading plan.

Najat Khan, Chief R&D Commercial Officer of Recursion Pharmaceuticals, acquired 84,925 Class A Common Stock units and 169,851 stock options under a pre-arranged plan.

Recursion Pharmaceuticals CEO Christopher Gibson executed a Rule 10b5-1 plan, converting Class B shares, selling Class A shares, and gifting additional Class A shares.

Recursion Pharmaceuticals CEO Christopher Gibson sold 100,000 shares of Class A Common Stock for $5.70 per share, following a conversion from Class B shares, under a pre-arranged 10b5-1 trading plan.

Recursion Pharmaceuticals CEO Christopher Gibson executed a planned sale and gift of Class A Common Stock on October 10, 2025, following a conversion of Class B shares.

Recursion Pharmaceuticals Director Dean Y. Li acquired 1,961 shares of Class A Common Stock as part of the company's established outside director compensation policy.

Zavain Dar, a Director at Recursion Pharmaceuticals, acquired 2,941 shares of Class A Common Stock as part of the company's director compensation policy.

Recursion Pharmaceuticals CEO Christopher Gibson sold 100,000 shares of Class A Common Stock for $4.76 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

CFO Ben Taylor reports 7,057 share disposition for tax withholding.

Recursion Pharmaceuticals CEO Christopher Gibson reported the sale of 100,000 Class A shares and conversion of Class B shares, all under a pre-arranged 10b5-1 plan.

Recursion Pharmaceuticals CEO Christopher Gibson executed a planned sale of 100,000 Class A Common Stock shares at $4.84 per share.

Recursion Pharmaceuticals' CFO, Ben R Taylor, reported a routine disposition of 11,908 Class A Common Stock shares to cover tax obligations related to restricted stock units.